Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers.

@article{Huhn1997PharmacodynamicsOS,
  title={Pharmacodynamics of subcutaneous recombinant human interleukin-10 in healthy volunteers.},
  author={Richard D. Huhn and Elaine Radwanski and James M. Gallo and Melton B. Affrime and Ron Sabo and G Gonyo and A. Sanchez Monge and David L. Cutler},
  journal={Clinical pharmacology and therapeutics},
  year={1997},
  volume={62 2},
  pages={171-80}
}
Interleukin-10 inhibits T-lymphocyte activation and proliferation and lipopolysaccharide-induced monocyte production of proinflammatory cytokines. Fifty-four healthy volunteers received single doses of recombinant human interleukin-10 (1.0, 2.5, 5.0, 10, 25, or 50 micrograms/kg) or placebo by subcutaneous injection (randomized double-blind assignment). Clinical adverse events were infrequent at doses below 50 micrograms/kg (five of six subjects had mild flu-like syndrome). Mean serum… CONTINUE READING